Engineered T-Cell CSF Infusion for Broader CNS Tumor Access
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tumor-specific T cell therapies for treating central nervous system cancers, such as high-grade malignant glioma, face challenges with insufficient tumor-specificity, activity duration, and access, limiting their therapeutic effectiveness.
Innovation Solution
Administering engineered T cells, such as CAR T cells or TCR-engineered T cells, into the cerebrospinal fluid (CSF) to target tumor antigens, allowing access to regions beyond the injection site and enabling large-volume infusions to treat both primary and secondary CNS malignancies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Volume of moving object
If T cells are administered intratumorally or to a cavity created by resection, then direct access to the tumor is achieved, but access to regions beyond the local site of injection is limited
Solution Approach 1:
The patent transitions from local intratumoral or intracavitary administration to intracerebroventricular administration, utilizing the cerebrospinal fluid pathway to distribute T cells throughout the entire central nervous system. This dimensional shift from localized to systemic distribution within the CNS enables access to multiple tumor sites and regions beyond the injection site, while maintaining ease of administration through established lumbar puncture or ventricular catheter techniques.
2Reliability
If conventional administration routes are used, then administration simplicity is maintained, but tumor-specificity and activity duration are insufficient
Solution Approach 1:
The patent modifies the administration parameter by using intracerebroventricular route with large-volume infusions (1 mL-2 mL or more) to enhance T cell distribution and persistence. This parameter change in administration volume and route enables better tumor-specificity and extended activity duration, while the administration system itself remains relatively simple, utilizing standard lumbar puncture or ventricular catheter techniques without requiring complex delivery mechanisms.
3Productivity
If large volumes of T cell composition are administered, then therapeutic effectiveness is improved, but administration complexity increases
Solution Approach 1:
The patent utilizes the hydraulic properties of cerebrospinal fluid to facilitate large-volume T cell administration. By injecting T cell composition into the CSF space, the fluid dynamics of the CSF circulation system naturally distribute the therapeutic cells throughout the CNS without requiring complex pumping or delivery mechanisms. This approach achieves improved therapeutic effectiveness through large-volume administration while avoiding the need for complicated administration equipment.
Data Source
AI summary
An improved method of treating cancers with engineered T cells is described.